LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been given a consensus rating of “Hold” by the nine research firms that are presently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $110.60.

Several equities research analysts recently weighed in on LMAT shares. Weiss Ratings lowered LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, August 14th. Wells Fargo & Company dropped their price objective on shares of LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 5th. Barrington Research downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Zacks Research lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Citigroup reiterated a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st.

LeMaitre Vascular Trading Up 0.3%

Shares of LMAT stock opened at $80.82 on Friday. The company has a quick ratio of 13.96, a current ratio of 16.31 and a debt-to-equity ratio of 0.40. The firm has a market cap of $1.85 billion, a P/E ratio of 28.36, a PEG ratio of 2.34 and a beta of 0.50. The company has a 50 day moving average of $86.01 and a 200-day moving average of $97.24. LeMaitre Vascular has a 12-month low of $78.22 and a 12-month high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.07). LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The firm had revenue of $70.38 million during the quarter, compared to analysts’ expectations of $71.47 million. During the same quarter in the previous year, the company posted $0.60 EPS. LeMaitre Vascular’s revenue for the quarter was up 9.6% on a year-over-year basis. Sell-side analysts anticipate that LeMaitre Vascular will post 2.89 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 3rd. Investors of record on Thursday, August 20th were issued a $0.25 dividend. The ex-dividend date of this dividend was Thursday, August 20th. This represents a $1.00 annualized dividend and a yield of 1.2%. LeMaitre Vascular’s dividend payout ratio (DPR) is 35.09%.

Institutional Investors Weigh In On LeMaitre Vascular

A number of hedge funds and other institutional investors have recently bought and sold shares of LMAT. Tidal Investments LLC purchased a new position in shares of LeMaitre Vascular in the second quarter valued at $526,000. Engineers Gate Manager LP lifted its holdings in LeMaitre Vascular by 38.4% during the 2nd quarter. Engineers Gate Manager LP now owns 14,008 shares of the medical instruments supplier’s stock worth $1,344,000 after purchasing an additional 3,888 shares in the last quarter. Nykredit A S purchased a new stake in LeMaitre Vascular during the 2nd quarter worth about $82,000. Corient Private Wealth LP boosted its stake in LeMaitre Vascular by 62.8% in the 2nd quarter. Corient Private Wealth LP now owns 25,589 shares of the medical instruments supplier’s stock worth $2,456,000 after purchasing an additional 9,875 shares during the period. Finally, Grandeur Peak Global Advisors LLC boosted its stake in LeMaitre Vascular by 63.1% in the 2nd quarter. Grandeur Peak Global Advisors LLC now owns 161,010 shares of the medical instruments supplier’s stock worth $15,451,000 after purchasing an additional 62,287 shares during the period. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures and markets medical devices used primarily in the treatment of peripheral vascular disease. Its products are designed for vascular surgeons and other specialists performing procedures on arteries and veins outside the heart and brain.

The company’s portfolio includes biologic and synthetic vascular grafts, thrombectomy catheters, angioplasty balloons, valvulotomes, vascular shunts, vessel-closure devices and other surgical instruments. LeMaitre also offers products used in vessel preparation, plaque removal and the repair or replacement of diseased blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular serves customers in the United States and international markets.